Stocksigma LogoStocksigma Logo

Aurobindo Pharma Subsidiary Launches ADQUEY in US, Targets $1.3B Dermatology Market

Aurobindo Pharma鈥檚 step-down subsidiary, Acrotech Biopharma, launched ADQUEY (difamilast 1% ointment) in the U.S

Aurobindo Pharma Subsidiary Launches ADQUEY in US, Targets $1.3B Dermatology Market

Aurobindo Pharma Ltd 路 Press Release 路 01 Oct 2026, 2:58 am

Aurobindo Pharma Subsidiary Launches ADQUEY in US, Targets $1.3B Dermatology Market Aurobindo Pharma鈥檚 step-down subsidiary, Acrotech Biopharma, launched ADQUEY (difamilast 1% ointment) in the U.S. on 30th Sep'26, marking its strategic entry into dermatology. Discovered by Otsuka Pharmaceutical and licensed to Acrotech, the non-steroidal topical PDE4 inhibitor treats mild-to-moderate atopic dermatitis in patients aged two and older. The product addresses an addressable U.S. market estimated at US$ 1.3 billion for the MAT ending Jul'26 (IQVIA). To support commercialization, Acrotech established a dedicated dermatology business unit covering marketing, sales, and field engagement.

Original exchange filing (PDF)

More announcements from Aurobindo Pharma Ltd

All Aurobindo Pharma Ltd announcements